Reading the tape
NASDAQ: CDXS
Codexis, Inc.
Healthcare · Biotechnology
Market Cap
$249.89M
52w High
$3.87
52w Low
$0.96
P/E
-5.65
Volume
1.72M
Outstanding Shares
90.87M
Price vs Fundamentals
Why The Stock Is Moving
Mixed / unclearLow confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: 6.97%Revenue (TTM): 18.61%FCF (TTM): 55.6%P/S: 26th pct
What changed
The stock rose 6.97% over the last year. Revenue grew 18.61% over the trailing twelve months. Operating margin moved from -98.61% to -54.46%. Free cash flow grew 55.6% over the trailing twelve months.
What the market seems to be pricing
The stock has moved higher against modestly improving underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
Operating margin currently stands at -54.46%. A decisive move in revenue — currently up 18.61% — would be the clearest signal to resolve the ambiguity.
Company profile
Codexis, Inc. discovers, develops, and sells enzymes and other proteins.
CEOAlison Moore
SectorHealthcare
IndustryBiotechnology
Employees188
IPO dateApr 22, 2010
Valuation
Forward P/E—
EV/EBITDA-5.47
Enterprise value$164.46M
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Revenue growth81.34%
Gross margin79.49%▲9.56%vs FY2024
Operating margin-54.46%▲44.77%vs FY2024
ROE-87.03%▲10.77%vs FY2024
Analyst consensus
RatingBuy
Target price$5.00▲81.82%
9
Buy
5
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 7, 2026
Q2 FY26 · EPS est -$0.16 · Revenue est $14.53M
View